These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24073705)

  • 1. Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications.
    Schiffmann L; Wedermann N; Gock M; Prall F; Klautke G; Fietkau R; Rau B; Klar E
    BMC Surg; 2013 Sep; 13():43. PubMed ID: 24073705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant-intensified treatment for rectal cancer: time to change?
    Musio D; De Felice F; Bulzonetti N; Guarnaccia R; Caiazzo R; Bangrazi C; Raffetto N; Tombolini V
    World J Gastroenterol; 2013 May; 19(20):3052-61. PubMed ID: 23716984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis of rectal cancer patients improves with downstaging by intensified neoadjuvant radiochemotherapy - a matched pair analysis.
    Schiffmann L; Klautke G; Wedermann N; Gock M; Prall F; Fietkau R; Rau B; Klar E
    BMC Cancer; 2013 Aug; 13():388. PubMed ID: 23947828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma.
    Zhu J; Gu W; Lian P; Sheng W; Cai G; Shi D; Cai S; Zhang Z
    Radiat Oncol; 2013 May; 8():130. PubMed ID: 23718210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Preoperative chemoradiotherapy for rectal cancer: experience from one centre].
    Lescut N; Lepinoy A; Schipman B; Cerda T; Guimas V; Bednarek C; Bosset JF
    Cancer Radiother; 2015 Apr; 19(2):98-105. PubMed ID: 25769650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease Control, Survival, and Toxicity Outcome After Intensified Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Single-Institution Experience.
    De Felice F; Musio D; Magnante AL; Bulzonetti N; Benevento I; Caiazzo R; Tombolini V
    Clin Colorectal Cancer; 2016 Jun; 15(2):e17-22. PubMed ID: 26952656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer.
    van Dijk TH; Tamas K; Beukema JC; Beets GL; Gelderblom AJ; de Jong KP; Nagtegaal ID; Rutten HJ; van de Velde CJ; Wiggers T; Hospers GA; Havenga K
    Ann Oncol; 2013 Jul; 24(7):1762-1769. PubMed ID: 23524865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncologically safe distal resection margins in rectal cancer patients treated with chemoradiotherapy.
    Kwak JY; Kim CW; Lim SB; Yu CS; Kim TW; Kim JH; Jang SJ; Kim JC
    J Gastrointest Surg; 2012 Oct; 16(10):1947-54. PubMed ID: 22878788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
    Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
    BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors for postoperative morbidity and tumour response after neoadjuvant chemoradiation followed by resection for rectal cancer.
    Berkel AE; Woutersen DP; van der Palen J; Klaase JM
    J Gastrointest Surg; 2014 Sep; 18(9):1648-57. PubMed ID: 24939597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer.
    Wang L; Li ZY; Li ZW; Li YH; Sun YS; Ji JF; Gu J; Cai Y
    Dis Colon Rectum; 2015 Feb; 58(2):186-92. PubMed ID: 25585076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of relatively low neoadjuvant radiation doses for locally advanced rectal cancer: A propensity score-matched analysis.
    Ye W; Shi L; Qian L; Sun Y; Sun X
    Cancer Rep (Hoboken); 2019 Oct; 2(5):e1188. PubMed ID: 32721108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
    Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
    J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer.
    Dellas K; Höhler T; Reese T; Würschmidt F; Engel E; Rödel C; Wagner W; Richter M; Arnold D; Dunst J
    Radiat Oncol; 2013 Apr; 8():90. PubMed ID: 23587311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen.
    Martijnse IS; Dudink RL; Kusters M; Vermeer TA; West NP; Nieuwenhuijzen GA; van Lijnschoten I; Martijn H; Creemers GJ; Lemmens VE; van de Velde CJ; Sebag-Montefiore D; Glynne-Jones R; Quirke P; Rutten HJ
    Ann Surg Oncol; 2012 Feb; 19(2):392-401. PubMed ID: 21792506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
    Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
    J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial.
    Uehara K; Hiramatsu K; Maeda A; Sakamoto E; Inoue M; Kobayashi S; Tojima Y; Yoshioka Y; Nakayama G; Yatsuya H; Ohmiya N; Goto H; Nagino M
    Jpn J Clin Oncol; 2013 Oct; 43(10):964-71. PubMed ID: 23935207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer.
    Velenik V; Oblak I; Anderluh F
    Radiat Oncol; 2010 Sep; 5():88. PubMed ID: 20920276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when, and for whom?
    De Stefano A; Moretto R; Bucci L; Pepe S; Romano FJ; Cella AC; Attademo L; Rosanova M; De Falco S; Fiore G; Raimondo L; De Placido S; Carlomagno C
    Clin Colorectal Cancer; 2014 Sep; 13(3):185-91. PubMed ID: 25080847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.